Targeting specific stem cells in myelodysplastic syndrome for better treatment outcomes
Metabolic targeting of heterogenous myelodysplastic syndrome stem cells
This study is looking to find better ways to treat high-risk myelodysplastic syndrome (MDS) by understanding the different types of stem cells involved in the disease and testing a new combination of drugs to help improve patient outcomes.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Colorado Denver NIH-funded |
| Lab location | 1 site (Aurora, UNITED STATES) |
| Project ID | NIH-10931676 on NIH RePORTER |
What this research studies
This research aims to identify and target the unique vulnerabilities of heterogeneous myelodysplastic syndrome (MDS) stem cells, which are believed to be the root cause of the disease. By understanding the different subsets of these stem cells and their varying responses to existing therapies, the project seeks to develop more effective treatment strategies. The approach includes laboratory studies and a clinical trial that tests a combination of drugs to improve patient outcomes. Patients with high-risk MDS may benefit from this innovative treatment strategy.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with high-risk myelodysplastic syndrome who have not responded adequately to current therapies.
Not a fit: Patients with low-risk myelodysplastic syndrome or those who have not been diagnosed with MDS may not receive any benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments that comprehensively eradicate MDS stem cells, potentially improving survival rates and quality of life for patients.
How similar studies have performed: Previous research has shown promising results in targeting MDS stem cells, but this approach aims to refine and improve upon those methods, making it a novel and potentially groundbreaking effort.
Where this research is happening
Aurora, UNITED STATES
- University of Colorado Denver — Aurora, United States (Active)
Researchers
- Principal investigator: Pietras, Eric M — University of Colorado Denver
- Study coordinator: Pietras, Eric M
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.